Condition: Prostate Adenocarcinoma · Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 · Stage IIC Prostate Cancer AJCC v8 · Sponsor: Jonsson Comprehensive Cancer Center
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
This description comes directly from the study's public registry record.
Vince Basehart · 310-267-8954 · vbasehart@mednet.ucla.edu
Maria Casado · 310-794-6913 · mcasado@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| University of California at Los Angeles / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04945642